City

Clinical trials near San Antonio, United States

Active studies with a listed research site in San Antonio, United States.

39active studies

21recruiting now

8countries represented

52largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Psoriasis, Overweight or ObesityCondition

TirzepatideTreatment

United States39 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06857942See eligibility →

Recruiting nowPhase 1

A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

Overweight, ObesityCondition

NNC0721-8060, SemaglutideTreatment

United States2 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07767175See eligibility →

Recruiting nowPhase 1

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Obesity, OverweightCondition

LY4174794, LY4174794Treatment

Singapore, United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-09-01 · NCT07654972See eligibility →

Recruiting nowPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Obesity or OverweightCondition

Maridebart CafraglutideTreatment

Puerto Rico, United States45 locations

AmgenSponsor

Updated 2026-08-27 · NCT07575399See eligibility →

Recruiting nowPhase 1

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Singapore, United States2 locations

Eli Lilly and CompanySponsor

Updated 2026-08-20 · NCT07738614See eligibility →

Recruiting nowPhase 2

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Condition

ALN-PNP, TirzepatideTreatment

United States6 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-08-10 · NCT07527910See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

Obesity, OverweightCondition

KAI-7535, PlaceboTreatment

Australia, United States36 locations

KaileraSponsor

Updated 2026-07-28 · NCT07497880See eligibility →

Recruiting nowPhase 2

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

ObesityCondition

NNC0662-0419, SemaglutideTreatment

Puerto Rico, United States25 locations

Novo Nordisk A/SSponsor

Updated 2026-07-10 · NCT07639021See eligibility →

Recruiting nowPhase 1

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

Weight ManagementCondition

GS-4571, PlaceboTreatment

United States3 locations

Gilead SciencesSponsor

Updated 2026-06-22 · NCT06562907See eligibility →

Recruiting nowPhase 2

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Overweight or Obesity and Elevated Liver FatCondition

Maridebart cafraglutide, PlaceboTreatment

United States23 locations

AmgenSponsor

Updated 2026-06-18 · NCT07441252See eligibility →

Recruiting nowPhase 2

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Obesity and Cardiovascular RiskCondition

Oral BGE-102, Oral Placebo Matching BGE-102Treatment

Puerto Rico, United States13 locations

BioAge Labs, Inc.Sponsor

Updated 2026-06-18 · NCT07656727See eligibility →

Recruiting nowPhase 2

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Type 2 DiabetesCondition

icovamenib 100 mg, PlaceboTreatment

United States17 locations

Biomea Fusion Inc.Sponsor

Updated 2026-06-15 · NCT07502508See eligibility →

Recruiting nowNot applicable

Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation

Post-COVID Conditions, ObesityCondition

12-weeks of Weight Loss, 12-weeks of Weight StabilityTreatment

United States2 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-06-01 · NCT05880108See eligibility →

Recruiting nowPhase 3

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Nausea and Vomiting, ObesityCondition

Tradipitant, PlaceboTreatment

United States10 locations

Vanda PharmaceuticalsSponsor

Updated 2026-04-20 · NCT07446439See eligibility →

Recruiting nowPhase 2

Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

Obesity Prevention, Sarcopenia in ElderlyCondition

TirzepatideTreatment

United States1 locations

The University of Texas Health Science Center at San AntonioSponsor

Updated 2026-04-15 · NCT06811324See eligibility →

Recruiting nowPhase 4

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

Spinal Cord Injuries, Type 2 DiabetesCondition

Semaglutide Injectable Product, PlaceboTreatment

United States2 locations

Marzieh SalehiSponsor

Updated 2026-04-13 · NCT06706284See eligibility →

Recruiting nowPhase 3

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Type 2 Diabetes (Adult Onset)Condition

Tirzepatide, PioglitazoneTreatment

United States2 locations

The University of Texas Health Science Center at San AntonioSponsor

Updated 2026-03-10 · NCT06246799See eligibility →

Recruiting nowPhase 1, Phase 2

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment

Hypothalamic Obesity, Prader-Willi SyndromeCondition

Part A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)Treatment

United States7 locations

Rhythm Pharmaceuticals, Inc.Sponsor

Updated 2025-12-22 · NCT06239116See eligibility →

Recruiting nowPhase 1

Prevention of Progression of Prediabetes, Obesity and CV Risk

Pre-Diabetes, Weight, BodyCondition

Placebo, Rybelsus TabletTreatment

United States1 locations

The University of Texas Health Science Center at San AntonioSponsor

Updated 2025-11-12 · NCT06446531See eligibility →

Recruiting nowPhase 4

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection FractionCondition

Pioglitazone, PlaceboTreatment

United States1 locations

The University of Texas Health Science Center at San AntonioSponsor

Updated 2025-08-27 · NCT05838287See eligibility →

Opening soonPhase 1

A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

End Stage Renal Disease, Renal ImpairmentCondition

RibupatideTreatment

United States1 locations

KaileraSponsor

Updated 2026-09-03 · NCT07793929See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Active, not recruitingPhase 1

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Overweight or Obesity, HealthyCondition

LY4064912, LY4064912Treatment

Singapore, United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-08-18 · NCT07152002See eligibility →

Active, not recruitingPhase 1

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

Obesity, OverweightCondition

NNC0638-0355, Placebo (NNC0638-0355)Treatment

Netherlands, United States4 locations

Novo Nordisk A/SSponsor

Updated 2026-08-17 · NCT06577766See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 1

A Study of LY3971297 in Healthy Participants

Healthy, ObesityCondition

LY3971297, PlaceboTreatment

Japan, Singapore7 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT06148272See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, PlaceboTreatment

United States35 locations

KaileraSponsor

Updated 2026-07-15 · NCT07458269See eligibility →

Active, not recruitingPhase 2

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Adult Obesity, Weight ManagementCondition

ECC4703, PlaceboTreatment

United States15 locations

EccogeneSponsor

Updated 2026-06-25 · NCT07505303See eligibility →

Active, not recruitingPhase 2

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

Overweight or ObesityCondition

Olatorepatide, PlaceboTreatment

United States3 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-06-17 · NCT07431086See eligibility →

Active, not recruitingPhase 1

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Obese But Otherwise Healthy ParticipantsCondition

CRB-913, PlaceboTreatment

United States15 locations

Corbus Pharmaceuticals Inc.Sponsor

Updated 2026-05-29 · NCT07310901See eligibility →

Active, not recruitingPhase 2

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

Obese, ObesityCondition

Aleniglipron, PlaceboTreatment

United States16 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-04-27 · NCT07400588See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

United Kingdom, United States31 locations

Eli Lilly and CompanySponsor

Updated 2026-04-17 · NCT07232719See eligibility →

Active, not recruitingNot applicable

Fit for Duty: mHealth Intervention for Weight Gain Prevention

ObesityCondition

Fit for Duty-mobile, m-Health ControlTreatment

United States1 locations

University of North Carolina, Chapel HillSponsor

Updated 2026-04-07 · NCT06110273See eligibility →

Active, not recruitingPhase 2

Taldefgrobep Alfa in Adults With Overweight and Obesity

Obesity, OverweightCondition

Taldefgrobep Alfa, PlaceboTreatment

United States20 locations

Biohaven Therapeutics Ltd.Sponsor

Updated 2026-03-20 · NCT07281495See eligibility →

Active, not recruitingPhase 2

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Endocrinology, Diabetes, Type IICondition

AZD6234, Placebo to matchTreatment

United States18 locations

AstraZenecaSponsor

Updated 2026-03-03 · NCT06851858See eligibility →

Active, not recruitingPhase 2

Aleniglipron Phase 2 Body Composition Study

Obesity, Overweight, or Chronic Weight ManagementCondition

aleniglipron or placeboTreatment

United States11 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-03-03 · NCT07169942See eligibility →

Active, not recruitingNot applicable

Promotion of Weight Management

OverweightCondition

Weight Maintenance, Weight Maintenance + Intermittent FastingTreatment

United States2 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-01-12 · NCT04131647See eligibility →

Active, not recruitingNot applicable

The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)

ObesityCondition

AGBSTreatment

United States17 locations

Allurion TechnologiesSponsor

Updated 2024-10-26 · NCT05368259See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near San Antonio, United States

Current studies

Related cities